Aveo Pharmaceuticals, Inc.

This study tested whether adding an immunotherapy drug (nivolumab) to a targeted therapy (tivozanib) helps people with advanced kidney cancer live longer without their cancer growing. The trial included 343 adults whose cancer had worsened after one or two prior treatments, inclu…